PuREC

Executive Summary

PuREC is a Japanese regenerative medicine company specializing in bone repair using its proprietary Rapidly-Expanding Cell (REC) platform. By purifying mesenchymal stem cells (MSCs), the company aims to create safer and more effective cell therapies for bone-related disorders. Founded in 2020 and headquartered in Tokyo, PuREC is currently in Phase 1 development. Its lead programs target hypophosphatasia (HPP), a rare genetic bone disease, and spinal canal stenosis, a common degenerative condition. The REC technology enables scalable production of highly potent MSCs, potentially addressing limitations of conventional cell therapies. PuREC's approach is differentiated by its focus on bone regeneration and the use of enriched MSCs, which may improve efficacy and safety profiles. While the company is still in early clinical stages, the unmet medical need in HPP and the large patient population for spinal stenosis provide significant market opportunities. Key upcoming catalysts include regulatory clearance to initiate clinical trials, first patient dosing, and potential partnership or funding announcements. With $5.8M raised to date, PuREC is well-positioned to advance its programs, though execution risk remains. The company's progress will depend on successful clinical validation and manufacturing scale-up.

Upcoming Catalysts (preview)

• Q3 2026Regulatory clearance to initiate Phase 1 trial for hypophosphatasia (HPP) program70% success
• Q4 2026First patient dosed in Phase 1 trial for HPP60% success
• TBDPartnership or grant announcement for spinal canal stenosis program50% success